Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France
Nivolumab in the adjuvant setting is likely to be cost-effective compared to surveillance in France.
Authors
- Lei Ni (ORCID: https://orcid.org/0000-0002-2632-3647)
- Sylvie Négrier
- Florian Colrat
- Julia Bonastre (ORCID: https://orcid.org/0000-0001-9884-0072)
- S. Branchoux
- C Knight (ORCID: https://orcid.org/0000-0001-6428-0505)
- Morgan Rouprêt (ORCID: https://orcid.org/0000-0001-8440-7075)
- Julie Chevalier (ORCID: https://orcid.org/0000-0002-3478-5729)
- S Teitsson (ORCID: https://orcid.org/0009-0001-7378-1675)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- La Ligue Contre le Cancer (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Bristol-Myers Squibb (France) (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Centre Léon Bérard (FR)
- Cryogel (France) (FR)
- Pitié-Salpêtrière Hospital (FR)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Onco-Urologie Prédictive
Publication Details
- Journal
- World Journal of Urology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1007/s00345-025-05589-2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Astellas Pharma
- Ipsen